Kainova Therapeutics
PrivateLast Round
Series B
Feb 10, 2026
Total Funding Raised
$72.91M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Kainova Therapeutics operates in Healthcare & Life Sciences and is based in Montreal. Its latest recorded funding round was a Series B round in February 2026.
Kainova Therapeutics is a biopharmaceutical company that develops breakthrough therapies targeting G protein-coupled receptors (GPCRs) for the treatment of immuno-oncology and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Kainova Therapeutics Comparables
Compare Kainova Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GPCR Therapeutics | 84% | |
| Confo Therapeutics | 84% | |
| Pathios Therapeutics | 82% |
For institutional investors. Book with your work email.
Kainova Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 10, 2026 | ||||
| Grant | Jan 25, 2024 | ||||
| Series A | May 10, 2022 | ||||
| Grant | Jan 27, 2022 | ||||
| Debt | Jan 13, 2020 | ||||
VC Round | May 28, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Kainova Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Investissement Québec | Series B |
| Idinvest Partners | VC Round |
| CTI Life Sciences Fund | Series B, Series A |
| Alsace Inter Regio Fonds d’Investissement | VC Round |
| Andera Partners | VC Round |
| Agence Nationale de la Recherche | Grant |
| 3B FUTURE Health Fund | Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors grew 33% MoM, reaching 1.8K.
- Feb 10, 2026
$24M round led by Investissement Québec
For institutional investors. Book with your work email.
Kainova Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Kainova Therapeutics's valuation, stock price, and market status.
Is Kainova Therapeutics a public or private company?
Kainova Therapeutics is a private company.
What is the current stock price of Kainova Therapeutics?
Kainova Therapeutics is a private company, so its shares have no public market price. Caplight tracks Kainova Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Kainova Therapeutics worth (valuation)?
Valuation information for Kainova Therapeutics is not publicly available.
Can I buy Kainova Therapeutics stock?
Kainova Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Kainova Therapeutics's last funding round?
Kainova Therapeutics's most recent funding round was Series B on February 10, 2026.
Who are the main investors in Kainova Therapeutics?
Key investors in Kainova Therapeutics include Investissement Québec, CTI Life Sciences Fund, 3B FUTURE Health Fund, Panacea Venture Healthcare, Seventure Partners.
Will Kainova Therapeutics IPO soon?
No public IPO plans have been announced for Kainova Therapeutics.
How can I track Kainova Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Kainova Therapeutics's shares on secondary markets.